CNTB
Connect Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CNTB
Connect Biopharma Holdings Limited
A biotech company developing therapies for inflammatory diseases and autoimmune disorders
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CALIFORNIA 92130
Development of a new generation of immunomodulators for severe autoimmune diseases and inflammation
Connect Biopharma Holdings Limited, incorporated in the Cayman Islands on November 23, 2015, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of a new generation of immunomodulators for severe autoimmune diseases and inflammation. The Group has leveraged its expertise in T-cell regulatory biology to build a portfolio of drug candidates consisting of small molecules and antibodies targeting key pathways of inflammation.
Company Financials
EPS
CNTB has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.24, missing expectations. The chart below visualizes how CNTB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CNTB has released its 2025 Q3 earnings report, with revenue of 16.00K, reflecting a YoY change of -98.69%, and net profit of -17.20M, showing a YoY change of -33.58%. The Sankey diagram below clearly presents CNTB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
